- Entity formation
- Entity management
- M&A transaction support
- Private capital & hedge fund core services
- Private capital
- Hedge fund
- Technology solutions
- Other funds services
- SPV corporate services
- Agency services
- Loan administration
- Cross capital market services
- Structures implementation and management
- Private client services
- Reporting services
Explore content
Show all >Featured articles and media

Insights | Corporate Client Services
Voluntary carbon credits bolster green bonds
25 May 2023
Read >
Featured articles and media
Show all media for Private Capital & Hedge Fund Services >Featured articles and media
Show all media for Capital Markets >Featured articles and media
Show all media for Private Clients >Featured events

Events | Virtual
Bankruptcy and Restructuring: Navigating Distress in the Evolving Markets
22 Jun 2023
Learn more >
Events | Virtual
Private Funds Industry Live, Expanding Private Funds in Global Markets
10 Jan 2023
Watch the recording >
Events | Virtual
Private Funds Industry Live, Demystifying Private Capital Funds
6 Dec 2022
Watch the recording >- Home
- Our services
- Corporate Client Services
- Entity formation
- Entity management
- M&A transaction support
- Private Capital & Hedge Fund Services
- Private capital & hedge fund core services
- Private capital
- Hedge fund
- Technology solutions
- Other funds services
- Capital Markets
- SPV corporate services
- Agency services
- Loan administration
- Cross capital market services
- Private Clients
- Structures implementation and management
- Private client services
- Reporting services
- Corporate Client Services
- Our locations
- About us
- News & Insights
- Login
Case study
Entering the Chinese market can be complex. This is how we helped Regenacy Pharmaceuticals with its expansion.
18 February 2021

The client
Regenacy Pharmaceuticals is a leading US biotech company, developing cutting edge, disease-modifying treatment for peripheral neuropathies – damaged nerve endings, resulting from a variety of medical conditions.
Having been founded in 2016, Regenacy Pharmaceuticals has successfully developed first-in-class potential treatments, and is moving on to the clinic trialing stage of drug development.
In order to support further research and clinical trials, Regenacy Pharmaceuticals will engage in a joint-venture partnership with strategic mainland Chinese partners.
Their challenge
Offering a number of structuring advantages, the most common route to market entry in China for foreign firms is via a Hong Kong holding company.
Unfamiliar with the local requirements to incorporate and maintain a legal entity in Hong Kong, Regenacy Pharmaceuticals sought a market leading services provider, with a deep expertise in end-to-end corporate services.
Our solution
Intertrust Group was recommended to Regenacy by their legal adviser, thanks to our long history of supporting US and European companies to enter the mainland Chinese market, and our expertise in establishing and maintaining Hong Kong investment vehicles.
Having successfully incorporated the Hong Kong company, Intertrust Group is also providing end-to-end corporate services to ensure that all of the local statutory obligations are satisfied to a high standard. Annual services include company secretary, registered office, accounting, audit liaison and tax compliance.
In addition, our team has a deep understanding of gathering the supporting documents required to register a WFOE (‘wholly foreign owned enterprise’) in mainland China. With Regenacy Pharmaceuticals in an exciting stage of their growth, we look forward to continuing to support their future expansion and success.